Meeting
2015 Gastrointestinal Cancers Symposium
Amrubicin monotherapy for patients with platinum-refractory gastroenteropancreatic neuroendocrine carcinoma.
Authors
Takayuki Ando
University of Toyama, Toyama, Japan
Takayuki Ando , Ayumu Hosokawa , Hiroki Yoshita , Akira Ueda , Shinya Kajiura , Hiroshi Mihara , Sohachi Nanjo , Haruka Fujinami , Jun Nishikawa , Toshiro Sugiyama
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Translational Research
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 328)
DOI
10.1200/jco.2015.33.3_suppl.328
Abstract #
328
Poster Bd #
B49
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Trends in treatment patterns associated with small cell lung cancer in a U.S. Medicare population.
First Author: Robert A. Ramirez
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Multicenter retrospective study of ramucirumab-containing chemotherapy for gastrointestinal neuroendocrine carcinoma patients previously treated with platinum-based chemotherapy: RAM-NEC study (WJOG13420G).
First Author: Hidekazu Hirano
Poster
2020 Gastrointestinal Cancers Symposium
A phase II trial of pembrolizumab in combination with cisplatin or carboplatin and etoposide in chemotherapy naive patients with metastatic or unresectable high-grade gastroenteropanncreatic or lung neuroendocrine carcinoma.
First Author: Robert A. Ramirez
Poster
2019 ASCO Annual Meeting
An open label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy and safety of TLC388 as second-line treatment in subjects with poorly differentiated neuroendocrine carcinomas (TCOGT1Z14).
First Author: Ming-Huang Chen